Drug Profile
IPH 1101
Alternative Names: IPH-1101; PhosphostimLatest Information Update: 21 Mar 2011
Price :
$50
*
At a glance
- Originator INSERM
- Developer Innate Pharma
- Class Antineoplastics; Phosphoric acid esters; Small molecules
- Mechanism of Action Cytokine stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic myeloid leukaemia; Follicular lymphoma; Hepatitis C; Malignant melanoma; Renal cancer
Most Recent Events
- 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Belgium (IV)
- 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in France (IV)
- 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Switzerland (IV)